Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta joining 2-3 (TRBJ2-3)
- Target
- TRBJ2-3
- Molecular classification
- Other, immature gene segment, immunoglobulin superfamily, T cell receptor gene segment
01
Overview
T cell receptor beta joining 2-3 (TRBJ2-3) is a gene segment encoding the joining region of the beta chain variable domain of the alpha-beta T cell receptor complex. This complex, expressed on T lymphocytes, is critical for antigen recognition and immune response. TRBJ2-3 participates in the V(D)J recombination process, generating the vast diversity of the T cell receptor repertoire, principally influencing the complementarity determining region 3 (CDR3) that directly contacts antigens presented on major histocompatibility complex (MHC) molecules. TRBJ2-3 is not itself a receptor protein nor a direct therapeutic target but is an essential component of adaptive immunity and is extensively used as a marker in immunological research, repertoire sequencing, and immune monitoring. Its gene rearrangement and expression profile provide insights into T cell development, antigen-specific memory, and clonal expansion in infections, cancer, and autoimmune diseases[1][2][3][4][5].
- Other names
- TRBJ2-3TRBJ23TCRBJ2S3TCRBJ23hCG_2039521
02
Biological functions
Adaptive immune responseAntigen recognitionGeneration of diversity in T cell receptor repertoire
03
Disease associations
Othernot a direct disease causerelevant for immune profilingvariants and clonal expansions used as biomarkers in infection, cancer, and autoimmunity
04
Safety considerations
No direct safety concernsManipulation of T cell repertoire in therapy can risk autoimmunity
05
Biomarkers
TCR repertoire clonalityCDR3 sequence diversityused in immune monitoringminimal residual disease detectionimmune profiling in infectious diseases and lymphoma
Beyond the preview
Go deeper on T cell receptor beta joining 2-3 (TRBJ2-3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor beta joining 2-3 (TRBJ2-3).